Ifabotuzumab (Synonyms: KB004) |
| Catalog No.GC69258 |
Ifabotuzumab (KB004)은 EphA3를 표적으로 하는 IgG1κ 항체(KD=610 pM)입니다. Ifabotuzumab는 종양 세포의 세포사멸을 유도하고 항체 의존성 세포 매개 독성 작용(ADCC)을 활성화하여 종양 혈관 시스템을 파괴할 수 있습니다. Ifabotuzumab는 CCR10+세포를 감소시켜 폐섬유증(IPF)을 개선할 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2147698-66-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Review for Ifabotuzumab
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for Ifabotuzumab
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *